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Summary
 
Treatment of WEHI 231 immature B lymphoma cells with an antibody against their surface
immunoglobulin M (anti-IgM) induces apoptosis and has been studied extensively as a model
of self-induced B cell tolerance. Since the tumor suppressor protein p53 has been implicated in
apoptosis in a large number of cell types and has been found to be mutated in a variety of B cell
tumors, here we sought to determine whether p53 and the p53 target gene cyclin-dependent
kinase inhibitor p21
 
WAF1/CIP1
 
 were involved in anti-IgM–induced cell death. Anti-IgM treat-
ment of WEHI 231 cells increased expression of p53 and p21 protein levels. Ectopic expression
of wild-type p53 in WEHI 231 cells induced both p21 expression and apoptosis. Ectopic ex-
pression of p21 similarly induced apoptosis. Rescue of WEHI 231 cells from apoptosis by co-
stimulation with CD40 ligand ablated the increase in p21 expression. Lastly, a significant de-
crease in anti-IgM–mediated apoptosis was seen upon downregulation of endogenous p53
activity by expression of a dominant-negative p53 protein or upon microinjection of an anti-
sense p21 expression vector or antibody. Taken together, the above data demonstrate impor-
tant roles for p53 and p21 proteins in receptor-mediated apoptosis of WEHI 231 B cells.
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T
 
he WEHI 231 lymphoma has been used as a model of
self-induced B cell tolerance (1). These cells express
surface IgM (1–3), and cross-linking of these surface immu-
noglobulin receptors with an anti-IgM antibody inhibits
DNA synthesis (1, 4). Anti-IgM treatment is followed by
cell cycle arrest in the late G
 
1
 
 phase followed by apoptosis
(5–8). Because of these features, WEHI 231 cells have been
used extensively as a model of clonal deletion of B cells, fa-
cilitating dissection of molecular pathways leading to cell
death. For example, we recently demonstrated that anti-
IgM treatment of these cells causes a drop in activity of the
nuclear factor (NF)-
 
k
 
B/Rel transcription factor family, re-
sulting in decreased c-
 
myc
 
 expression and induction of cell
death (9–12).
A growing number of gene products have been revealed
as components of the machinery leading to cell death.
Among these, p53 is of particular interest. The p53 protein,
originally identified as a cellular nuclear phosphoprotein
bound to the large transforming antigen of the SV40 DNA
virus (13, 14), has been shown to play important roles in
control of progression through G
 
1 
 
into S phase, DNA re-
pair, differentiation, tumor formation, and apoptosis (15–
17). Induction of p53 is often associated with activation of
cell death, and ectopic expression of p53 can induce apop-
tosis (18). Thymocytes and hematopoietic cells from mice
lacking a p53 gene show resistance to radiation and drug-
induced apoptosis (19, 20), and fibroblasts from these mice
show resistance to apoptosis (21). Interestingly, anti-IgM–
induced cell death of immature B cells from mice null for
the p53 gene was significantly reduced (22). The mecha-
nism by which p53 exerts these effects is not clear, but
seems to depend on the ability of p53 protein to act as a
transcription factor.
One of the important p53 transcriptional target genes is
the cyclin-dependent kinase (CDK)
 
1
 
 inhibitor p21
 
WAF1/CIP1
 
(23–26). The p21 protein can convert active CDK to inac-
tive species, controlling and coordinating cell cycle pro-
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gression (27). The increase in p21 levels elicited by p53
protein upon cellular damage caused by irradiation or other
toxic agents leads to CDK inhibition and cell cycle arrest
(28, 29). Moreover, p21 activity has been implicated in ap-
optosis. Ectopic p21 expression induces cell death in MCF-7
breast carcinoma cells, and p21 levels increase during apop-
tosis of the RT4 human bladder tumor cell line (30–32).
These findings suggest that at least some of the ability of
p53 to promote apoptosis is mediated through its effects on
p21 expression. Here we have investigated the involve-
ment of p53 and its putative target gene p21 in apoptosis of
WEHI 231 cells induced by anti-IgM treatment. Our re-
sults indicate p53 and p21 play important roles as interme-
diates in receptor-mediated apoptosis of these immature B
lymphoma cells.
 
Materials and Methods
 
Cell Culture and Treatment Conditions.
 
WEHI 231 cells were
maintained at 37
 
8
 
C in DMEM supplemented with 10% fetal bo-
vine serum (FBS), 0.35% glucose, 4 mM glutamine, nonessential
amino acids, 100 U/ml penicillin, 100 
 
m
 
g/ml streptomycin, and
50 
 
m
 
M 2
 
-
 
ME as previously described (9). Before treatment, cells
were diluted to a density of 4 
 
3 
 
10
 
5
 
 cells/ml with fresh warm
media and allowed to incubate for a minimum of 4–5 h. Cells
were treated with 1:1,000 dilution anti-
 
m 
 
heavy chain antibody
(anti-IgM, GIBCO BRL, Gaithersburg, MD) for the indicated
periods of time. For cotreatment with CD40 ligand (CD40L) and
anti-IgM, WEHI 231 cells were incubated with CD40L fusion
protein (1:10), consisting of the extracellular domains of CD40L
and CD8
 
a
 
, and anti-CD8 (1:100) plus anti-IgM, as previously
described (33). Stable temperature-sensitive p53-transfected WEHI
231 cells, prepared as described below, were cultured at 38.5
 
8
 
C.
Where indicated, untreated cultures were shifted to 32.5
 
8
 
C to in-
duce wild-type p53 activity.
 
Cell Death Assays.
 
For analysis of DNA laddering, 
 
z
 
10
 
6 
 
cells
were used per sample according to the procedure of Smith et al.
(34) as we have previously described (10, 11). For trypan blue
analysis, cells were incubated with 0.2% trypan blue for 10–20
min and the percentage of cells excluding dye (viable cells) deter-
mined by examination under phase-contrast microscopy at 
 
3
 
100.
 
Construction of Transfected Cell Lines.
 
Electroporation of WEHI
231 cells was performed essentially as described (9, 10). WEHI
231 cells in exponential growth were washed once with medium
and resuspended at a concentration of 2 
 
3 
 
10
 
7
 
 cells/ml in
DMEM supplemented with 20% FBS. Cells (250 
 
m
 
l) were prein-
cubated on ice for 10 min with DNA (20–40 
 
m
 
g). Cells were
transfected by electroporation at 240V and 960 
 
m
 
F using a Gene
Pulser (Bio-Rad, Hercules, CA). After incubation on ice for 5
min, the cell suspension was mixed with 1.75 ml of complete me-
dium, and incubated for 10 min at room temperature. Cell cul-
tures were incubated for 48 h at 37
 
8
 
 C before selection.
Stably transfected WEHI 231 cell lines expressing a tempera-
ture-sensitive p53 dominant negative protein were prepared using
the expression vector pLTRp53cGVal135 (35–37). This vector
expresses a p53 mutant in which alanine at position 135 is re-
placed with valine (35). WEHI 231 cells were electroporated
with 40 
 
m
 
g DNA plus 2 
 
m
 
g of pSV2neo vector as a selectable
marker. After 24–48 h, 1,000 
 
m
 
g/ml G418 (GIBCO BRL) was
added to the cells, and cultures were maintained under antibiotic
selection for 
 
z
 
2 wk. Individual clones were obtained via limiting
dilution. WEHI 231 cells transfected with pSV2neo DNA alone
were used as controls.
For preparation of p21 inducible expression WEHI 231 cell
lines, a modification of the Lac-Switch inducible mammalian ex-
pression vector (Stratagene, La Jolla, CA) was used. This system
consists of p3
 
9
 
SS, a eukaryotic vector carrying the 
 
lacI
 
 gene ex-
pressing lac-repressor, and a eukaryotic lac operator–containing
vector pOPRSVICAT driven by the RSV-LTR. To construct
an inducible p21 expression vector, the HindIII and NotI cDNA
fragment, which encodes full-length p21 protein, was excised
from a human cDNA vector (pBS-p21A, gift of Dr. Y. Xiong,
University of North Carolina, Chapel Hill, NC), and used to re-
place the chloramphenicol acetyl transferase (CAT) reporter gene
in the pOPRSVICAT vector, generating a clone termed pO-
PRSVI-p21. Cells were electroporated with 30 
 
m
 
g pOPRSVI-
p21 and 10 
 
m
 
g p3
 
9
 
SS, and selected for stable transfectants under
350 
 
m
 
g/ml hygromycin B (Boehringer Mannheim GmbH, Mann-
heim, Germany) and 1,000 
 
m
 
g/ml G418 to isolate mixed popula-
tions of p21 expressing cells, which were used in the experiments.
As a control, cells were transfected with p3
 
9
 
SS only and selected
with hygromycin.
 
Immunoblot Analysis.
 
For nuclear protein extraction, cells
were washed twice in cold PBS and resuspended in cold TKM
10-10-5 (10 mM Tris-HCl, pH 7.6, 10 mM KCl, and 5 mM
MgCl
 
2
 
) with 0.2 mM PMSF and 10 
 
m
 
g/ml leupeptin. After incu-
bation on ice for 10 min, cells were lysed by addition of NP-40
to 0.5% (final concentration). Nuclei were removed by centrifu-
gation and nuclear protein were extracted with RIPA buffer (10
mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% SDS,
1% sodium sarcosyl, 0.2 mM PMSF, 10 
 
m
 
g/ml leupeptin, and 1
mM dithiothreitol) as previously described (11). For total cellular
protein isolation, the PBS-washed cell pellets were extracted with
RIPA as above. Protein samples (20 
 
m
 
g for nuclear protein and
50 
 
m
 
g for total protein) were fractionated on a 10 or 12% poly-
acrylamide/SDS gel and transferred to polyvinylidene fluoride
membrane. Immunoblotting was performed as previously de-
scribed (11). The antibodies used were: p53, Pab 421 (Oncogene
Science, Cambridge, MA); p21, sc-397 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA); c-Myc, 50-23, an affinity-purified murine
c-Myc specific antibody (provided by S. Hann, Vanderbilt Uni-
versity, Nashville, TN) (38).
 
Northern Blot Analysis.
 
Cytoplasmic RNA was isolated from
2 
 
3 
 
10
 
6
 
 cells per sample. Cells were washed twice in ice cold
PBS, resuspended in 400 
 
m
 
l of cold TKM, and swelled on ice for
10 min. After lysis upon addition of 20 
 
m
 
l 10% NP-40, the nuclei
were removed by centrifugation. The resulting cytoplasmic su-
pernatant was extracted with phenol/chloroform/isoamyl alcohol
(10:10:1). RNA was precipitated from the aqueous supernatant
with 0.1 vol of 3 M NaAc (pH 5.2) and 2.5 vol of absolute etha-
nol, and dissolved in diethyl pyrocarbonate–treated water. The
p53 probe pLTRp53cGVal135 (35) was labeled by the random
primer method of Feinberg and Vogelstein (39). Hybridization
was performed as previously described (40).
 
Microinjection Analysis.
 
For microinjection analysis, a pO-
PRSVI-p21 construct with reverse orientation of the p21 cDNA
insert was prepared. This vector expresses a noncoding p21 tran-
script (antisense) and was termed pOPRSVI-anti-p21. Similarly, a
human p27 cDNA insert was cut from vector pGlu-p27H (pro-
vided by Dr. Y. Xiong) with HindIII and BamHI, and used to
replace the CAT gene of pOPRSVICAT in an orientation yield-
ing expression of antisense p27 RNA. This expression vector was
termed pOPRSVI-anti-p27. Alternatively, affinity-purified anti- 
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body preparations against p21 or p27 (sc-397 and sc-528, respec-
tively; Santa Cruz Biotechnology) were used.
WEHI 231 cells were allowed to attach to tissue culture plastic
in the presence of culture medium containing 0.4% FBS, and
were supplemented with 20 mM Hepes, pH 7.3. After 30 min of
incubation at 37
 
8
 
C, duplicate areas (containing 
 
z
 
200–300 cells/
sample) were encircled. For microinjection of expression plas-
mids, DNA samples were adjusted to 1 
 
m
 
g/
 
m
 
l in 130 mM KCl,
and 10 mM sodium phosphate buffer, pH 7.3. Microinjections
were performed using a Narishige micromanipulator (Narishige
Co., Ltd., Tokyo, Japan) and borosilicate glass capillaries (tip di-
ameter: 0.2 
 
m
 
m) under conditions of constant nitrogen flow at
0.4 pounds per square inch. After microinjection, cloning rings
were placed over the microinjected areas and the medium was re-
placed with 10% FBS/DMEM. After 30 min of incubation at
37
 
8
 
C, cells were removed by gentle trituration, transferred to
multiwell plates, and incubated at 37
 
8
 
C in the presence of anti-
IgM. After 45 h, 0.1 vol trypan blue solution (0.04% final) was
added to the wells and the wells were incubated for another 15
min, then the percentage of trypan blue positive was determined
by phase-contrast microscopy. Alternatively, cells were microin-
jected with 4 
 
m
 
g of affinity-purified antibody in the absence or
presence of cognate peptide. After microinjection, cells were
treated with anti-IgM and processed after 18 h, as above.
 
Results
 
Anti-IgM Treatment of WEHI 231 Cells Induces p53 Pro-
tein Expression.
 
As an initial assessment of the contribu-
tion of p53 to receptor-mediated apoptosis of WEHI 231
cells, the expression of p53 protein after anti-IgM treat-
ment was analyzed. Nuclear proteins were isolated from
cells treated with anti-IgM for 0, 2, 4, 6, 8, 10, or 12 h, and
were subjected to immunoblotting using a mouse mono-
clonal anti-p53 antibody. As seen in Fig. 1 
 
a
 
, untreated cells
(0 h) expressed a low but detectable level of p53 protein.
By 2 h of stimulation, p53 levels had increased 
 
z
 
2.7-fold,
and levels peaked between 4 and 6 h after treatment. Com-
pared with untreated control cells, p53 levels had increased
6.2- and 6.7-fold, respectively, by 4 and 6 h. Between 10
and 12 h, p53 protein levels gradually returned to baseline
values (2.1- to 1.1-fold). Thus, apoptosis initiated by anti-
IgM treatment leads to a relatively rapid increase in p53
protein expression; the rise in p53 levels was similar to that
seen in other cell types induced to undergo cell death (18).
To assess whether the p53 protein that was induced after
anti-IgM treatment was functional, we next determined
whether expression of the CDK inhibitor p21, previously
shown to be transcriptionally activated by p53 (23–26), fol-
lowed a kinetic profile consistent with p53-mediated acti-
vation. Total cellular proteins were extracted from WEHI
231 cells treated with anti-IgM for the same time course as
above, and subjected to immunoblot analysis for p21 ex-
pression (Fig.1 
 
b
 
). The low levels of p21 protein found in
untreated cells were increased at 2 h after stimulation; the
levels peaked at 6–8 h, and remained elevated throughout
the 12-h time course. The kinetics of the observed changes
in p21 expression paralleled, but were delayed with respect
to, p53 induction. Thus, p53 expression increases after
anti-IgM treatment, and p21 protein levels are elevated in a
manner consistent with functionally active p53.
 
Ectopic Expression of p53 Induces Apoptosis of WEHI 231
Cells.
 
To determine whether ectopic expression of p53
protein can induce the death of WEHI 231 cells, stably
transfected WEHI 231 cell lines expressing a temperature-
sensitive murine p53 protein were prepared by using the
expression vector pLTRp53cGVal135 (35). At the nonper-
missive temperature of 32.5
 
8
 
C, these transfectants express a
p53 that is wild type; at 38.5
 
8
 
C, they express a dominant-
negative p53 that abrogates the endogenous p53 function
(35–37).
Northern and immunoblot analyses were used to verify
the ectopic expression of p53 in the pLTRp53cGVal135
transfected lines maintained at 38.5
 
8
 
C. Cytoplasmic RNA
Figure 1. Anti-IgM treat-
ment induces p53 and p21 pro-
teins. (a) p53 analysis. Nuclear
proteins were isolated from ex-
ponentially growing WEHI 231
cells treated with anti-IgM for 0,
2, 4, 6, 8, 10, or 12 h, and sam-
ples (20 mg) were subjected to
immunoblotting for p53 expres-
sion with a mouse monoclonal antibody. Detection was achieved using a
horseradish peroxidase–conjugated secondary antibody and chemilumi-
nescence as previously described (10). (b) p21 analysis. Total cellular pro-
teins were prepared from WEHI 231 cells treated with anti-IgM for 0, 2,
4, 6, 8, 10, or 12 h, and samples (50 mg) were subjected to immunoblot-
ting for expression of the CDK inhibitor p21 using an affinity-purified
rabbit antibody (sc-397; Santa Cruz Biotechnology).
Figure 2. Expression of p53 and p21 in the temperature-sensitive p53
cell lines. WEHI 231 cell lines were electroporated with 40 mg DNA of
pLTRp53cGVal135 ts p53 expression vector (35) plus 2 mg of pSV2Neo
vector as a selective marker, and p53#11, p53#13, and p53#16 stable
lines obtained by limiting dilution. Similarly, WEHI 231 cells were trans-
fected with 2 mg of pSV2Neo alone to establish a population of control
cells (Neo). Cell lines were maintained at 38.58C where p53 is in a domi-
nant negative mutant form. (a) p53 RNA analysis. Cytoplasmic RNA was
isolated from clones p53#11 and p53#16 lines and pSV2Neo cells, and
samples (20 mg) subjected to Northern blotting using the murine p53
DNA pLTRp53cGVal135 as probe (35). Bottom panel shows ethidium
bromide staining of the 28S and 18S rRNA on the Northern blot, which
indicates equal loading and RNA integrity. (b) p53 protein analysis. Total
cellular proteins were extracted with RIPA buffer from p53#11, p53#16
and control Neo cells, and samples (50 mg) subjected to immunoblotting
using the p53 antibody Pab421. (c) p21 protein analysis. Cultures of
p53#11 and p53#16 cell lines were kept at 38.58C or switched to 32.58C,
and total cellular proteins isolated after 24 h. Samples (50 mg) were ana-
lyzed for p21 protein by immunoblotting using an affinity purified rabbit
antibody against p21 protein (sc-397, Santa Cruz Biotechnology). 
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was isolated from clones p53#11 and p53#16 and pSV2Neo
cells, and samples subjected to Northern blotting (Fig. 2 
 
a
 
).
At the nonpermissive temperature, clones p53#11 and p53#16
expressed high levels of p53 mRNA, whereas barely de-
tectable levels of p53 were noted in the pSV2Neo clone.
Ethidium bromide staining of the 28S and 18S rRNA in
the gel indicated equal loading and integrity of the RNA
samples. Furthermore, ectopic expression of p53 protein
was confirmed using immunoblotting of total protein ex-
tracts from the above cell lines (Fig. 2 
 
b
 
). Lastly, to verify
that these clones expressed functional p53 in a temperature-
dependent fashion, the effects of a temperature shift on en-
dogenous p21 expression were monitored (Fig. 2 
 
c
 
). 24 h
after shifting to the permissive temperature, p21 protein
levels were dramatically induced. These results confirm that
the transfectants express a functional p53 protein.
 
Ectopic Expression of p53 Induces Apoptosis of WEHI 231
Cells.
 
To determine whether induction of p53 expression
activates apoptosis, DNA fragmentation assays were per-
formed. The p53 clones p53#11, p53#16, and Neo cells
were analyzed 24 h after a temperature switch to 32.5
 
8
 
C.
Significant DNA laddering was observed after induction of
wild-type p53 expression in the p53#11 and p53#16 cell
lines (Fig. 3 
 
a
 
). As expected, only a low basal level of DNA
laddering was detectable in the Neo cells after 24 (Fig. 3 
 
a
 
)
or 48 (data not shown) h. Thus, ectopic expression of wild-
type p53 is sufficient to induce apoptosis of WEHI 231
cells.
To obtain more quantitative assessment of this killing,
analysis of cell viability was performed using trypan blue
exclusion at various times after temperature shift. The
p53#11, p53#16, and control Neo cells were cultured in
duplicate at 32.5
 
8C for 0, 24, 48, or 72 h, and trypan blue–
positive cells were measured. Fig. 3 b shows that both clone
p53#11 and p53#16 exhibited a steady increase in cell
death during the time course; the percentage of dead cells
increased from 7% (in both) on day 0 to 82 and 84% on day
3 in the p53#11 and p53#16 cultures, respectively. In con-
Figure 3. Induction of apoptosis by ec-
topic p53 expression. (a) DNA laddering.
The p53 expressing clones p53#11,
p53#16, and control Neo cells were cul-
tured at 32.58C for 0 or 24 h, and subjected
to DNA ladder assays (34), as a measure of
induction of apoptosis. (b) Trypan blue
staining. The p53 expressing clones p53#11
(hatched bars), p53#16 (open bars) and control
Neo (filled bars) cells were cultured in dupli-
cate at 32.58C for 0, 24, 48, or 72 h in 96-
well dishes, and induction of cell death de-
termined by trypan blue staining. Numbers
of cells stained trypan are plotted as a func-
tion of time in hours. The statistical signifi-
cance was obtained using the Student’s t
test, and the vertical bars represent the stan-
dard deviation.
Figure 4. Downregulation of endogenous p53 activity inhibits anti-IgM–induced apoptosis. (a) The p53 expressing clone p53#11 and Neo control
cells were grown at 38.58C and treated with anti-IgM for 0, 20, or 32 h, and analyzed for apoptosis by DNA ladder assays (left panel). Alternatively,
p53#11 and Neo control cells were cultured in duplicate at 38.58C and treated with anti-IgM for 48 h, and cell death was analyzed by trypan blue stain-
ing (right panel). Data are plotted as the mean percentage of cells stained positive for trypan blue. The statistical significance was obtained using the Stu-
dent’s t test, and the vertical bars represent the standard deviation. (b) The p53-expressing clone p53#16 and Neo control cells were cultured at 38.58C
and treated with anti-IgM for 48 h, and analyzed as above. Alternatively, p53#16 and Neo control cells were cultured in duplicate at 38.58C and treated
with anti-IgM for 0 or 48 h, and analyzed by trypan blue staining for cell death. Data are plotted as above.1675 Wu et al.
trast, only a modest increase in cell death was observed
with the Neo clone (from 7 to 12%). These results demon-
strate that overexpression of p53 protein is sufficient to in-
duce apoptosis of WEHI 231 cells.
Downregulation of Endogenous p53 Activity Inhibits Anti-
IgM–induced Apoptosis. To determine whether p53 ex-
pression is necessary for anti-IgM–induced apoptosis, p53
clones p53#11, p53#16, and Neo cells were cultured at
38.58C and treated with anti-IgM for 20, 32, or 48 h, as in-
dicated. DNA fragmentation was extensive in the Neo cells
treated with anti-IgM for 20 or 32 h (Fig. 4 a), or 48 h
(Fig. 4 b), as expected. In contrast, inhibition of endoge-
nous p53 in clone p53#11 (Fig. 4 a) and clone p53#16
(Fig. 4 b) greatly reduced DNA fragmentation in compari-
son with the Neo clone. Quantitative analysis of cell death
in these clones in response to 48 h of anti-IgM treatment
was obtained using trypan blue exclusion. Clones p53#11
and p53#16 demonstrated significant protection against
anti-IgM–induced apoptosis compared with the Neo con-
trol line (Fig. 4, a and b). The percentage of cell death was
reduced from 80% in the Neo line to 25 and 35% in clones
p53#11 and p53#16, respectively. Similarly, in the mixed
population of p53 transfectants, the percentage of cell death
was reduced from 76.5 to 47.3% after treatment with anti-
IgM for 48 h at 38.58C (data not shown). Thus, absence of
functional p53 activity allows for significant rescue of
WEHI 231 cells from receptor-mediated apoptosis.
Ectopic Expression of p21 Induces Apoptosis of WEHI 231
Cells. The above results indicate that p53 induction is
sufficient to induce apoptosis, and that p53 induces p21 ex-
pression. To determine whether p21 induction alone is suf-
ficient to produce apoptosis, stable WEHI 231 cells con-
taining an inducible p21 expression vector were prepared
using a modification of the isopropyl-b-d-thiogalacto-pyran-
oside (IPTG)-inducible LacSwitch expression vector sys-
tem. This modified version consists of the p39SS vector
carrying the lacI gene, and a lac operator–containing eu-
karyotic expression vector pOPRSVICAT, in which the
CAT reporter gene was replaced by a full length cDNA in-
sert encoding p21; this new vector was termed pOPRSVI-
p21. Stably transfected WEHI 231 cells were prepared with
a combination of pOPRSVI-p21 and p39SS vector, or with
p39SS vector alone, as control. A pool of stable transfectants
were treated with 20 mM IPTG for 24 h to induce p21
protein expression; this dose of IPTG was found sufficient
to inactivate the repressor protein (data not shown). Total
cellular proteins were prepared and subjected to immuno-
blotting analysis to verify induction of p21 expression. IPTG
treatment induced p21 expression in the population of pO-
PRSVI-p21 transfectants, but not in the control p39SS cells,
as expected (Fig. 5 a). To determine whether ectopic expres-
sion of p21 induced cell death, cultures were treated with
20 mM IPTG for 24 h and subjected to DNA fragmentation
analysis. IPTG treatment of the population of pOPRSVI-
p21 transfectants resulted in significant DNA fragmentation,
whereas similar treatment of control p39SS cells showed es-
sentially no DNA fragmentation (Fig. 5 b). To more quan-
titatively measure cell death induced by p21 expression,
cultures were treated in duplicate with 20 mM IPTG for 0,
14, 24, or 42 h, and cell viability was assessed via trypan
blue staining (Fig. 5 c). A time-dependent increase in cell
death was noted with the pOPRSVI-p21 transfectant pop-
ulation. By 42 h after treatment, z45% of the cells were
dead. In contrast, only a slight 8% change in cell death was
observed with the control p39SS cells. Similarly, 31.0 6 2.8%
of WEHI 231 cells microinjected with the p21 expression
vector were trypan blue positive after 18 h compared with
5.2 6 2.0% of cells not microinjected or 6.5 6 0.8% of
Figure 5. Ectopic expression of p21 induces WEHI 231 cell death. WEHI 231 cells were electroporated with 30 mg pOPRSVI-p21 and 10 mg p39SS
vector encoding the Lac I repressor and a mixed population of p21 transfectants were selected using 350 mg/ml hygromycin B and 1,000 mg/ml G418. Al-
ternatively, WEHI 231 cells electroporated with control p39SS were selected with hygromycin alone. (a) p21 protein analysis. Total proteins were pre-
pared from pOPRSVI-p21 and control p39SS transfected cells after treatment with 20 mM IPTG for 24 h, and samples (50 mg) were subjected to immu-
noblot analyses for expression of p21. (b) DNA ladder assay. Cultures of the control pOPRSVI-p21 and p39SS transfected cells were treated with 20 mM
IPTG for 24 h and analyzed for apoptosis by a DNA ladder assay. (c)Trypan blue staining. Cultures of the pOPRSVI-p21 and p39SS transfected cells were
treated in duplicate with 20 mM IPTG for 24 h, and extent of cell death was assessed by trypan blue staining. Data are plotted as the mean percentage of
cells stained positive for trypan blue. The statistical significance was obtained using the Student’s t test, and the vertical bars represent the standard devia-
tion.1676 Roles of p53 and p21 in Receptor-mediated WEHI 231 B Cell Apoptosis
cells microinjected with pBluescript vector DNA (data not
shown). Taken together, these results demonstrate that ec-
topic p21 expression leads to apoptosis of WEHI 231 cells.
CD40L Rescue of Anti-IgM–induced Apoptosis Correlates
with Decreased Expression of p21. CD40L rescue of WEHI
231 cells from anti-IgM–induced apoptosis is accompanied
by maintenance of NF-kB/Rel and c-myc expression (33),
as well as of cellular proliferation (41). To determine whether
CD40L affected p21 expression in response to anti-IgM
treatment, exponentially growing WEHI 231 cells were
treated with anti-IgM in the presence or absence of CD40L
for 0, 8, or 12 h. Total cellular proteins were extracted, and
samples were subjected to immunoblotting for p21 protein
expression (Fig. 6). Treatment with anti-IgM alone led to
the expected induction in p21 protein levels. However, in-
duction of p21 was significantly ablated by cotreatment
with CD40L plus anti-IgM (Fig. 6). Thus, CD40L-induced
rescue of WEHI 231 cells from receptor-mediated apopto-
sis is accompanied by a block in the induction of the CDK
inhibitor p21.
Reduction of CDK Inhibitor Expression Ablates Anti-IgM–
induced Apoptosis. Since induction of p21 was sufficient to
induce apoptosis of WEHI 231 cells, and CD40L rescue
prevented the normal increase seen upon anti-IgM treat-
ment, we next sought to determine whether the receptor-
mediated increase in p21 expression was a necessary part of
the signal transduction pathway(s) leading to apoptosis.
WEHI 231 cells were microinjected with pOPRSVI-anti-
p21, a plasmid yielding inducible expression of p21 transcript
in an antisense orientation, and then treated immediately
with anti-IgM. After incubation at 378C for 45 h, cultures
were analyzed for cell viability (Fig. 7). Treatment of non-
microinjected cells with anti-IgM induced death in 60 6
1.4% of the cells after 45 h, as previously seen (11). In con-
trast, only 38.7 6 6.8% of pOPRSVI-anti-p21 microin-
jected cells were dead (P ,0.05, Student’s t test). Thus, an-
tisense p21 is capable of inducing a significant amount of
protection against anti-IgM–induced apoptosis. Recently,
anti-IgM treatment has also been shown to induce expres-
sion of another CDK inhibitor, p27Kip1 (42). Thus, the
effects of antisense expression of p27 in combination with
antisense p21 on anti-IgM–mediated apoptosis were simi-
larly assessed. The combination of antisense p21 and anti-
sense p27 provided very significant protection, superior to
that with the p21 vector alone. Cells microinjected with
the combination of vectors exhibited 15.4 6 1.1% cell
death at 45 h after treatment with anti-IgM.
To inhibit p21 activity more directly, cells were also mi-
croinjected with affinity purified antibodies to either p21
or p27 protein, and the effects on anti-IgM–mediated kill-
ing assessed. After 18 h, in the absence of microinjection,
41.9 6 0.1% of cells were trypan blue positive, and this
value was essentially unaffected by microinjection of BSA
protein. In contrast, microinjection of an antibody against
p21 protein significantly reduced the level of cell death
(24.4  6  0.1%), and this was specific as judged by reversal of
protection upon incubation with the cognate peptide. Mi-
croinjection of the peptide alone did not affect cell viability
(data not shown). Again, inhibition of both p21 and p27
protected to even a greater extent (only 13.7 6 1.5% cell
death). The specificity of the effect of the p27 antibody was
also confirmed with its cognate peptide (data not shown).
Thus, these results indicate that a portion of the signals
leading to apoptosis is dependent on p21; many of the re-
maining signals appear mediated via a p27 pathway.
Discussion
The results presented here indicate that induction of p53
and p21 proteins after anti-IgM treatment is part of a criti-
cal pathway in receptor-mediated apoptosis of WEHI 231
B cells. Treatment of WEHI 231 cells with anti-IgM led to
early increases in p53 protein expression and subsequently
Figure 6. CD40L rescue of
anti-IgM–induced apoptosis is
accompanied by a block in in-
duction of p21 expression.
WEHI 231 cultures were treated
with anti-IgM in the absence (2) or presence (1) of CD40L for the indi-
cated times, and total cellular proteins were prepared and samples (20 mg)
were subjected to immunoblot analysis for p21 expression.
Figure 7. Antisense p21 and antisense p27 expression ablates anti-IgM–
induced apoptosis. (a) WEHI 231 cells were microinjected with the indi-
cated plasmids at a concentration of 0.5 mg/ml, and with enough pBluescript
plasmid to bring the final DNA concentration to 1.0 mg/ml. Immediately
after microinjection, cells were treated with anti-IgM and cultured for 45 h,
and cell viability was assessed by trypan blue staining. Data are presented
as the mean of duplicates, with standard deviation indicated. This data
represents one experiment that is typical of three independent experi-
ments with essentially identical results. The total number of cells analyzed
per treatment ranged from 163 (asp21 1 asp27) to 231 (none). (b) WEHI
231 cells either were not microinjected (none) or were microinjected with
4 mg/ml. BSA or affinity-purified antibody against p21 protein in the ab-
sence or presence of 4 mg/ml cognate peptide or 4 mg/ml affinity-purified
antibody against p27 protein. Immediately after microinjection, cells were
treated with anti-IgM and cultured for 18 h, and cell viability was assessed
by trypan blue staining. Data are presented as the mean of duplicates, with
standard deviation indicated. This data represents one experiment that is
typical of two independent experiments with essentially identical results.
The total number of cells analyzed per treatment ranged from 135 (BSA)
to 231 (anti-p21).1677 Wu et al.
to increases in p21 protein levels. Ectopic expression of
wild-type p53 induced both p21 expression and apoptosis.
Consistent with a direct role for induction of p21 in cell
death, ectopic expression of p21 alone also induced apop-
tosis of WEHI 231 cells. Furthermore, downregulation of
endogenous p53 activity by expression of a dominant-neg-
ative p53 protein or by p21 antibody or antisense expres-
sion significantly ablated receptor-mediated apoptosis. Taken
together, the above data demonstrate a pivotal involvement
of p53 in anti-IgM–induced apoptosis of WEHI 231 B
cells, which is probably mediated, at least in part, by the
product of its target gene p21.
Mounting evidence, both in vitro and in vivo, supports a
role for p53 function in control of B cell fate. Mutations of
the p53 gene have been reported in 41% of Burkitt’s lym-
phomas, 60% of B cell chronic lymphocytic leukemia, and
30% of high-grade non-Hodgkin’s lymphomas (for reviews
see references 43, 44). In addition, a recent report found
p53 abnormalities in 75% of B cell prolymphocytic leuke-
mia (45). Analysis of B cell tumors from p53-null mice re-
vealed significantly decreased levels of immunoglobulin
deposition when compared with tumors from wild-type
mice (22). Furthermore, the p53-null mice contained more
immature B cells in the bone marrow compared with wild-
type mice. Importantly, these effects appear to relate to loss
of normal receptor-mediated killing of these immature B
cells (46). Treatment of the immature B cell population
from p53-null mice with anti-IgM resulted in hyperprolif-
eration (46) rather than the typical cell death response seen
with immature B cells from normal mice (22), suggesting a
role of p53 in control of B cell death. Furthermore, wild-
type p53 has been implicated as a control protein in the dif-
ferentiation pathway of B cells. Ectopic expression of wild-
type p53 protein promotes differentiation of the Abelson
murine leukemia virus–transformed pre-B cell line L12
(47). Differentiation of the pre-B cell line 70Z/3 in re-
sponse to lipopolysaccharide is accompanied by increases in
p53 expression (48). Lastly, ectopic expression of a domi-
nant-negative p53 mutant is capable of blocking LPS-medi-
ated differentiation (48).
Our work extends the list of genes whose protein prod-
ucts are involved in receptor-induced apoptotic pathways
of WEHI 231 cells. Recent work from our lab has impli-
cated the NF-kB/Rel transcription factor family and the
c-myc oncogene as important intermediates in the signal
transduction pathway leading to apoptosis (10, 11). Ectopic
expression of either c-myc or c-rel prevents anti-IgM medi-
ated apoptosis; direct inhibition of either c-Myc or Rel ac-
tivity induces death of WEHI 231 cells (10, 11, 49). One
potential model for relating the findings of this work to our
previous studies is to postulate that c-myc is upstream of
p53. Anti-IgM treatment leads to a transient increase by 1 h
followed by eventual downmodulation of NF-kB/Rel ac-
tivity; these modulations precede concomitant changes in
transcription of the c-myc gene, which is strongly regulated
by NF-kB/Rel in these cells (9). Interestingly the p53 pro-
moter has been found to be activated by c-Myc in fibro-
blasts (50,51). Furthermore, p53 has been found to repress
c-myc transcription in a human glial cell line (52), and we
have observed that induction of wild-type p53, in our tem-
perature-sensitive p53 lines, led to downregulation of c-myc
expression (data not shown). Thus, one can propose that
the initial increase in c-Myc expression leads to induction
of p53, which then participates in promoting the subse-
quent downregulation of c-myc expression. The potential
interrelationships between c-Myc and p53 expression after
anti-IgM treatment, which are probably complex, are cur-
rently under investigation.
Anti-IgM has been previously shown to induce expres-
sion of p27 protein (42), although the mechanism is un-
known. The evidence presented here suggests that p21 and
p27 cooperate in mediating anti-IgM–induced apoptosis, as
judged by the antisense experiments. Thus, these observa-
tions implicate p27 in receptor-mediated apoptosis in
WEHI 231 cells. The fact that neither antisense reagent
alone gives full protection suggests a divergence in path-
ways leading to apoptosis of these B cells: portions of the
apoptotic signals initiated after cross-linking of surface IgM
channel through p21 and others through p27. Thus, these
findings suggest the existence of parallel signal transduction
pathways diverging from the initiating events mediated by
receptor–ligand interaction and working together to pro-
mote apoptosis.
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